Question to the Home Office:

To ask the Secretary of State for the Home Department, when the Advisory Council on the Misuse of Drugs review of cannabis-based products for medicinal use is expected to be completed and published.

Cannabis-based products for medicinal use (‘CBPMs’) were placed in Schedule 2 to the Misuse of Drugs Regulations 2001 in 2018, making them available for prescribing.

The Government has commissioned the Advisory Council on the Misuse of Drugs (‘ACMD’) to review the evidence on CBPMs and assess whether the legislative change in 2018 has had the desired effect and whether there have been any unintended consequences.

The ACMD is an independent scientific advisory body and determines its own procedures. However, the three-year Ministerial commission for 2025 – 2028 flagged the CBPM commission as a priority.

The Government will consider the advice carefully before deciding what action to take. The response will be published on gov.uk.